literature

HIV mutation literature information.

Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors.

PMID: 10770770 2000 Antimicrobial agents and chemotherapy

Abstract: The mutations included the following: I15V, E35D, N37D, R41K, D60E, and A71T.

Reduced antiretroviral drug susceptibility among patients with primary HIV infection.

PMID: 10501117 1999 JAMA

Abstract: Population-based sequence analysis of these 3 samples identified multidrug-resistance mutations in reverse transcriptase (M184V, T215Y, K219K/R) and protease (L101/V, K20R, M361, M46I, G48V, L63P, A71T, V771, V82T, 184V, L90M) in the 2 latter patient samples, along with numerous polymorphisms.

Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.

PMID: 8643685 1996 Proc Natl Acad Sci U S A

Abstract: The clone-purified RF (G48V/A71T/V82A) virus, unlike the corresponding defective NL4-3 triple mutant, grew well and displayed cross-resistance to four distinct protease inhibitors.

Abstract: The predominant breakthrough virus contained the G48V/A71T/V82A protease mutations.

Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor.

PMID: 7884862 1995 Journal of virology

Abstract: Further genotypic analysis of the protease genes from earlier passages of virus indicated that the A71T mutation emerged prior to the V82A change.

Abstract: Genetic analysis of the protease gene from a drug-resistant variant revealed an Ala-to-Thr change at amino acid residue 71 (A71T) and a Val-to-Ala change at residue 82 (V82A).

Abstract: To determine the effects of these mutations on protease and virus drug susceptibility, recombinant protease and proviral HIV type 1 clones containing the single mutations A71T and V82A or double mutation

Browser Board

Co-occurred Entities

Filtrator